Status:
COMPLETED
L-Carnosine for Bipolar I Disorder
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Conditions:
Bipolar I Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Our hypothesis is that oral L-carnosine treatment (as compared with placebo) will enhance cognitive abilities (specifically: measures of attention, executive function, working memory, visuospatial abi...
Detailed Description
OBJECTIVE: It is our hypothesis that L-carnosine treatment of persons with bipolar illness will improve their cognitive outcomes, more specifically, measures of attention and executive function, verb...
Eligibility Criteria
Inclusion
- DSM IV - TR diagnosis of bipolar I disorder or
- Ages 18 to 65 years
- Men or Women
- Ability to read and communicate in English
- 8th grade education or greater
- Ability to provide informed, competent and written consent
- Current medication and mood status (Y-MRS and MADRS scores less than or equal to 10) is stable for greater than or equal to 4 weeks.
Exclusion
- Medically unstable conditions
- Known allergy to L-carnosine
- Current cognitive decline is attributable to a diagnosis of dementia or other neurological disorder, including HIV dementia or cognitive decline
- Pregnant or lactating women
- Mini-mental state examination score (MMSE) less than or equal to 23.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00177463
Start Date
September 1 2004
End Date
December 1 2007
Last Update
January 11 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayview State Hospital
Bridgeville, Pennsylvania, United States, 15017
2
Mon-Yough Community Services, Inc.
McKeesport, Pennsylvania, United States, 15132
3
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, United States, 15213